Macleod Pharma plans Big Pharma IPO

Last Updated: Dec 11, 2022 - 06:32 pm 57.6k Views

Macleod Pharma is one of the largest non-listed pharma plays in India. Macleod Pharma was floated by Dr. Rajendra Agarwal in 1986 to manufacture anti-tuberculosis drugs in India. The big news is that Macleod Pharma may be considering an IPO shortly, although they are yet to file the DRHP with SEBI. The IPO of Macleod Pharma was already doing rounds after the rip-roaring success of the Gland Pharma IPO last year.

It is being estimated that in terms of size, the Macleod Pharma IPO could be next only to Gland Pharma, which had raised Rs.6,480 crore through its IPO last year. In the last couple of years, pharma IPOs like Laurus Labs, Gland Pharma and Eris Life Sciences have done phenomenally well post listing. COVID-19 and the sudden rush for APIs and specialized generics is leading to a positive re-rating of pharma companies. Clearly, Macleod is planning its IPO to be in the right place at the right time.

Macleod Pharma has a rich 35 year legacy with strong focus on anti-tubercular, Anti-malarial, anti-bacterial, anti-retroviral and anti-diabetic medicines. Currently, Macleod has 14 manufacturing facilities for finished dosage and 2 facilities for manufacturing APIs. Macleod is a vertically integrated pharma company manufacturing close to 25 billion units of finished dosages annually. These include tablets, capsules, liquids, orals, inhalers, dry powders etc.

Macleod reaches out to over 150,000 doctors in India. Some of its popular brands in the market include Omnacortil, Lulimac, Budetrol, Defcort, Geminor, Vildamac, Olmesar, Nexovas, Thyrox, Tenlimac, Enzomac, Macfolate, Meromac, Tazomac, Montemac and Rebagen.

How do you rate this blog?


Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Open Free Demat Account
Resend OTP
Please Enter OTP
Account belongs to

By proceeding, you agree to the T&C.

Latest Blogs
Swing Trading Stocks: Week of 3 October 2023

Swing Trading Stocks for the Week

  • Sep 29, 2023
Weekly Outlook on Gold - 29 September 2023

Gold prices are facing sustained pressure despite a backdrop of dollar weakness, a rare occurrence that coincides with a decline in yields on US Treasuries. Typically, the strength of the dollar and higher yields have been key components of the Federal Reserve's hawkish monetary policy.

  • Sep 29, 2023
Weekly Market Outlook for 3 October to 6 October

The last week of September turned out to be volatile as the markets corrected during the monthly expiry to test the 19500 mark. We witnessed a strong recovery in Friday’s session, and the index finally ended the week above 19600, with marginally weekly loss.

  • Sep 29, 2023